Cytokinetics posts Q3 2026 results, plans nHCM filing for aficamten in Q4
The company reported $44.5 million in MYQORZO net product revenue and said it expects to submit a supplemental approval application for aficamten in non-obstructive HCM before year end.
Cytokinetics reported financial results for the third quarter of 2026 on November 4, 2026. The company presented positive primary results from the ACACIA-HCM Phase 3 trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy at a Hot Line Session at the European Society of Cardiology Congress, with findings also published in the New England Journal of Medicine.1 Based on those results, the company said it expects to file a Supplemental New Drug Application for nHCM in the fourth quarter of 2026, and a Type II Variation in the European Union in early 2027.1
On the commercial side, MYQORZO received authorization from Health Canada and marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency for symptomatic obstructive HCM in adult patients, and NICE recommended it for use in eligible adults in England and Wales.1 Cytokinetics said it expects to launch MYQORZO in the United Kingdom in the fourth quarter of 2026 and in additional countries in 2027.1
In the pipeline, the company completed the main study treatment period of CAMELLIA-HCM, a Phase 3 trial of aficamten in Japanese patients with obstructive HCM being conducted by Bayer in collaboration with Cytokinetics to support potential marketing authorization in Japan.1 It also completed the adolescent cohort of CEDAR-HCM, a pediatric trial of aficamten in obstructive HCM, and expects to present topline data in early 2027.1 Enrollment continues in COMET-HF, a confirmatory Phase 3 trial of omecamtiv mecarbil in heart failure with severely reduced ejection fraction, with enrollment expected to continue through 2027.1
On finances, the company held approximately $1.6 billion in cash, cash equivalents and investments as of September 30, 2026, compared with $1.7 billion at June 30, 2026.1 Total revenue for the quarter was $47.6 million, including $44.5 million in MYQORZO net product revenue.1 Cytokinetics reaffirmed its full-year 2026 guidance of $860 million to $890 million in combined GAAP research and development and selling, general and administrative expense.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.